INmune Bio FY2022 net loss $27.3M; XPro AD trial under FDA clinical hold

Inmune Bio, Inc.

Net loss $27.3M vs $30.3M in 2021; R&D expense $17.1M; cash $52.2M at Dec 31, 2022.
FDA clinical hold on XPro AD trial in US continues; enrollment ongoing in Australia and Canada.
Phase 2 AD trial topline readout expected 2H 2024; trial consolidated to include MCI patients.
IND for INKmune in mCRPC to be filed March 2023; Phase I/II trial planned.
Received ~$6.4M in R&D rebates from Australia and UK; will reinvest in recruitment.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Inmune Bio, Inc. reported financial results for the year ended December 31, 2022.

Period: the year ended December 31, 2022
Result: reported results

Exact text from the filing

INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announces its financial results for the year ended December 31, 2022 and provides a business update.

View on SEC.gov

Browse all earnings releases →

Inmune Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-23-017274

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.